A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Huabo Biopharm Co., Ltd.
Huabo Biopharm Co., Ltd.
Tolmar Inc.
Stella Pharma Corporation
Gene Solutions
A2 Biotherapeutics Inc.
BriaCell Therapeutics Corporation
VitaMed Research LLC
Concr